Related Experiment Video
Updated: Aug 8, 2026

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model
Published on: June 11, 2020
Myocarditis following rAd26 and rAd5 vector-based COVID-19 vaccine: case report
Farah Naghashzadeh1, Shadi Shafaghi1, Atosa Dorudinia2
1Lung Transplantation Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Abstract:
SARS-CoV-2 vaccines provide a safe solution with a major impact on reducing the spread of the virus and mild side effects. Research has shown rare cases of myocarditis after mRNA vaccines. This study presents a 29-year-old male with chest pain after 48 h of receiving rAd26 and rAd5 vector-based COVID-19 vaccine (Sputnik V vaccine). The electrocardiogram revealed ST-segment elevation. Also, the laboratory screening was remarkable for elevated cardiac Troponin-I level, and leukocytosis; and echocardiography depicted severe left ventricular systolic dysfunction. Overall, endomyocardial biopsy proved lymphocytic myocarditis such that the patient was successfully treated with immunosuppressive and guideline-directed medical treatment.
Related Concept Videos
Endocarditis I: Introduction
Endocarditis III: Medical Management
Myocarditis I: Introduction
Myocarditis II: Clinical Features and Diagnostic Tests
Myocarditis III: Medical Management
Myocarditis IV: Nursing Management

